



KOCHINSTITUTE
for Integrative Cancer Research at MIT

A unique approach to cancer research

Matthew Vander Heiden



science + engineering =
conquering cancer together

Brief Koch Institute History

1971



The National Cancer Act of 1971

Public Law 92-218
92nd Congress, S. 1828
December 23, 1971

An Act

To amend the Public Health Service Act so as to strengthen the National Cancer Institute and the National Institutes of Health in order more effectively to carry out the national effort against cancer.

1974



NCI·CC

A Cancer Center Designated by the National Cancer Institute



Former factory
dedicated for
cancer research

By Stephen Blatt

2011



NCI Cancer Center

A Cancer Center Designated by the
National Cancer Institute



The Koch Institute at MIT




- > 192,000 NASF
- 25 members located in the Koch Institute building
- 32 members located in neighboring buildings
- 2 clinical investigators
- > 700 staff

Kendall Square and the Boston Technology Cluster



Koch Institute Mission

To develop **new insights** into cancer, as well as **new tools** and **technologies** to better **detect**, **monitor**, and **treat** the disease.





Dan Anderson



Angela Belcher




Sangeeta Bhatia



Michael Birnbaum



Jianzhu Chen



Michael Cima



Paula Hammond



Michael Hemann



David Housman



Omer Yilmaz



Michael Yaffe



Dane Wittrup



Forest White



Matthew Vander Heiden



Stefani Spranger




Phillip Sharp



Ram Sasisekharan



Scott Manalis



Christopher Love



Jackie Lees



Richard Hynes



Darrell Irvine



Tyler Jacks




Angela Koehler



Robert Langer



Cross-Disciplinary Research



The Core Facilities of the Swanson Biotechnology Center



Basement:

High Throughput Sciences

Nanotechnology Materials

Flow Cytometry

Integrated Genomics & Bioinformatics (server)

Zebrafish Facility

Glassware Preparation

Media Preparation



Level 1:

Histology

Biopolymers & Proteomics

Integrated Genomics & Bioinformatics

Preclinical Modeling, Imaging & Testing



Level 2:

Flow Cytometry


Microscopy




Level 7:

Preclinical Modeling, Imaging & Testing

The Koch Institute Core Facilities



Biopolymers
& Proteomics




Flow Cytometry




Glassware



High Throughput
Sciences




Histology




Integrated Genomics
& Bioinformatics




Media Preparation



Microscopy



Nanotechnology
Materials




Preclinical Modeling,
Imaging & Testing




Zebrafish


Koch Institute Focus Areas




Detection & Monitoring




Metastasis



Precision Medicine



Nano-Based Drug Delivery



Immunology

cross-cutting themes traversing multiple cancer types
and applied at all stages of the research pipeline



Koch Institute Signature Programs and Centers



FRONTIER RESEARCH PROGRAM



MIT
STEM
CELL
INITIATIVE



MIT CENTER FOR
PRECISION
CANCER MEDICINE



The Bridge Project




- > Philanthropically funded
- > Collaborative partnership with Dana-Farber/ Harvard Cancer Center



Measuring Biophysical Properties of Single Cells

Suspended Microchannel Resonator (SMR)




Burg et al. Nature 2007

Resonant frequency shift is directly proportional to single-cell buoyant mass

Precision is <0.1% (50 femtograms)

Serial SMR Array





Cermak et al. Nature Biotech. 2016


Mass accumulation rate




THE BRIDGE PROJECT



Mass accumulation rate as a predictive biomarker



Tumor Oxygen Measurements to Guide Therapy for Cervical Cancer Patients




- Poor clinical outcomes for low oxygen tumors and low oxygen tumors are known to be more resistant to radiation therapy
- New clinical device: oxygen sensor that may guide where to increase brachytherapy radiation dose to tumors with low oxygen levels
- First MR guided HDR brachytherapy with oxygen sensor performed July 2019

Clinical Implementation




Clinical Oxygen Sensor Design




For High Dose Brachytherapy



Activity-Based Nanosensors for Disease Monitoring and Detection




Imaging extracellular matrix changes to detect cancer





KPC GEMM with PanIN




Proteomic analyses of ECM



Microdevices to assess drug response




Microdevices to assess drug response



Davidson et al., Nature Med, 2017

Improving Early Detection of Breast Cancer



New federal law requires mammography providers to send breast density notifications

Michael Walter | February 19, 2019 | *Policy*



When President Donald Trump signed a federal funding bill into law on Feb. 15, it included text that said that all mammography providers must include updated information about breast density in reports sent to both patients and their physicians.

Breast Density Assessments Vary even Among Expert Radiologists

Annals of Internal Medicine

ORIGINAL RESEARCH

Variation in Mammographic Breast Density Assessments Among Radiologists in Clinical Practice

A Multicenter Observational Study


Brian L. Sprague, PhD; Emily F. Conant, MD; Tracy Onega, PhD; Michael P. Garcia, MS; Elisabeth F. Beaber, PhD; Sally D. Herschorn, MD; Constance D. Lehman, MD, PhD; Anna N.A. Tosteson, ScD; Ronilda Lacson, MD, PhD; Mitchell D. Schnall, MD, PhD; Despina Kontos, PhD; Jennifer S. Haas, MD, MSc; Donald L. Weaver, MD; and William E. Barlow, PhD; on behalf of the PROSPR Consortium*

Results: Overall, 36.9% of mammograms were rated as showing dense breasts. Across radiologists, this percentage ranged from 6.3% to 84.5% (median, 38.7% [interquartile range, 28.9% to 50.9%]), with multivariable adjustment for patient characteristics having little effect (interquartile range, 29.9% to 50.8%).

KI Contribution: Density Assessment Using Deep Learning

Mammographic Breast Density Assessment Using Deep Learning: Clinical Implementation



Constance D. Lehman, MD, PhD • Adam Yala, MEng • Tal Schuster, MSc • Brian Dontchos, MD • Manisha Bahl, MD, MPH • Kyle Swanson, BS • Regina Barzilay, PhD




Non Dense	6021 (93.6%)	413 (6.4%)
Dense	201 (4.6%)	4128 (95.4%)
	Non Dense	Dense


DL Model

Clinical Implementation



Can AI Predict Future Breast Cancer?





KOCHINSTITUTE
for Integrative Cancer Research at MIT

science + engineering = conquering cancer together

ki.mit.edu

